{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:48:49Z","timestamp":1780710529292,"version":"3.54.1"},"reference-count":99,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, physiologically based PharmacoKinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics. It has been demonstrated to be informative and helpful to quantify the modification in drug exposure due to specific physio\u2010pathological conditions, age, genetic polymorphisms, ethnicity and particularly drug\u2013drug interactions (DDIs). In this paper, the prediction success of DDIs involving various cytochrome P450 isoenzyme (CYP) modulators namely ketoconazole (a competitive inhibitor of CYP3A), itraconazole (a competitive inhibitor of CYP3A), clarithromycin (a mechanism\u2010based inhibitor of CYP3A), quinidine (a competitive inhibitor of CYP2D6), paroxetine (a mechanism\u2010based inhibitor of CYP2D6), ciprofloxacin (a competitive inhibitor of CYP1A2), fluconazole (a competitive inhibitor of CYP2C9\/2C19) and rifampicin (an inducer of CYP3A) were assessed using Simcyp<jats:sup>\u00ae<\/jats:sup>software. The aim of this report was to establish confidence in each CYP\u2010specific modulator file so they can be used in the future for the prediction of DDIs involving new victim compounds. Our evaluation of these PBPK models suggested that they can be successfully used to evaluate DDIs in untested scenarios. The only noticeable exception concerned a quinidine inhibitor model that requires further improvement. Additionally, other important aspects such as model validation criteria were discussed.<\/jats:p>","DOI":"10.1002\/bdd.2107","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T16:03:47Z","timestamp":1506614627000},"page":"3-17","source":"Crossref","is-referenced-by-count":38,"title":["Prediction of drug\u2010drug interactions using physiologically\u2010based pharmacokinetic models of CYP450 modulators included in Simcyp software"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5727-4035","authenticated-orcid":false,"given":"Niloufar","family":"Marsousi","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology Geneva University Hospitals Switzerland"},{"name":"School of Pharmaceutical Sciences Geneva and Lausanne Universities Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules A.","family":"Desmeules","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology Geneva University Hospitals Switzerland"},{"name":"School of Pharmaceutical Sciences Geneva and Lausanne Universities Switzerland"},{"name":"Swiss Center for Applied Human Toxicology (SCAHT) University of Basel Switzerland"},{"name":"Faculty of Medicine Geneva University Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Rudaz","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences Geneva and Lausanne Universities Switzerland"},{"name":"Swiss Center for Applied Human Toxicology (SCAHT) University of Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Daali","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology Geneva University Hospitals Switzerland"},{"name":"School of Pharmaceutical Sciences Geneva and Lausanne Universities Switzerland"},{"name":"Swiss Center for Applied Human Toxicology (SCAHT) University of Basel Switzerland"},{"name":"Faculty of Medicine Geneva University Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058099"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb00001.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(95)02822-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00008"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050420"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04453.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin\u2010fluconazole. II. A metabolically based drug interaction: in vivo studies","volume":"24","author":"Black D. J.","year":"1996","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.49"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.83"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-014-0235-4"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb05614.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316471"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.052241"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90056-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.08.004"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00207-G"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.016"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00099.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1999.tb02019.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-009-3441-1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0762-z"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.40.7.1715","article-title":"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers","volume":"40","author":"Gillum J. G.","year":"1996","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90146-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90176-X"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90172-2"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.036103"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03799.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.27"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90031-4"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.4.474"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104788"},{"key":"e_1_2_8_33_1","first-page":"613","article-title":"Pharmacokinetic interactions of nifedipine and quinidine","volume":"50","author":"Hippius M.","year":"1995","journal-title":"Die Pharmazie"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(25)08415-6","article-title":"The nifedipine\u2010rifampin interaction. Evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker N.","year":"1996","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.320"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.167"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-016-0059-9"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.53"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050437"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0090-9556(25)07354-4","article-title":"Metoprolol metabolism via cytochrome P4502D6 in ethnic populations","volume":"24","author":"Johnson J. A.","year":"1996","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.37"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.291"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90046-1"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.10.013"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2165\/00003088-200342110-00004","article-title":"Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine","volume":"42","author":"Kim M. K.","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.02.022"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111414"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003259216"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200023336992"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03201.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04216.x"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050439"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.45"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199200221-00015"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922012015"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602530903210716"},{"key":"e_1_2_8_57_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole","volume":"276","author":"Moltke L. L.","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(97)00044-7"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90167-8"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90165-5"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90059-4"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008326716"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111183"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.116511"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199603000-00015"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.60"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.7.630"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004269521"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.8581"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02970.x"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.271"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2004.10.002"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2173"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.52"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065920"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.177"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-199912000-00007"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.30"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.128"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198700341-00035"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008331133"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010365559"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000194497.55269.d9"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04111.x"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70009-3"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198106113042405"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007369"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.184"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90176-4"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90082-5"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0188-4"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0330-y"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.33"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000794"},{"key":"e_1_2_8_95_1","unstructured":"World Health Organization (WHO)(2010).Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment. Available from:http:\/\/www.who.int\/ipcs\/methods\/harmonization\/areas\/pbpk_models.pdf?ua=1."},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050715"},{"key":"e_1_2_8_97_1","first-page":"400","article-title":"Interaction between midazolam and clarithromycin: comparison with azithromycin","volume":"34","author":"Yeates R. A.","year":"1996","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_8_98_1","article-title":"What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the U.S. FDA in 2015","author":"Yu J.","year":"2016","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.77"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.68"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:50:03Z","timestamp":1750891803000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/bdd.2107"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2107","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]}}}